About Escientia Advanced Sciences Private Limited
Data last updated: 17 December 2025
Escientia Advanced Sciences Private Limited is a private limited company based in Shameerpet, Telangana, India, a subsidiary of Deccan Advanced Sciences Pvt Ltd. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 27 February 2013, the company has been in operation for over 13 years.
Registered with ROC Hyderabad under CIN U24100AP2013PTC085962.
Capital: an authorised share capital of ₹22 Cr and a paid-up capital of ₹21.49 Cr. It is led by directors including Srinivasa Rao Korada and Pendri Kiran Reddy.
Last AGM: 20 December 2024. Financial statements filed for year ended 31 March 2024. Office: Surveyno.542/02 Plot No:Ds /14 Ikp Knowledge Park Kolthur Village, Shameerpet, Telangana, India – 500078.
As per the financials filed for FY 2024, the company reported a revenue of ₹423.15 Cr, a growth of 114% compared to the previous year.
The company has a workforce of approximately 295 employees as per the latest available data. It operates as a subsidiary of Deccan Advanced Sciences Pvt Ltd.
The company is associated with 1 brand - Escientia Lifesciences. As per MCA filings, the company has open charges of ₹100 Cr and satisfied charges of ₹85 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website escientia.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media**************
-
Registered AddressSurveyno.542/02 Plot No:Ds /14 Ikp Knowledge Park Kolthur Village, Shameerpet, Telangana, India – 500078
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Escientia Advanced Sciences Private Limited
Escientia Advanced Sciences Private Limited has one previous CIN (Corporate Identification Number): U24100AP2013PTC085962. The current CIN is U24100TG2013PTC085962, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24100TG2013PTC085962 | Current |
| U24100AP2013PTC085962 | Previous |
Associated Brands with Escientia Advanced Sciences Private Limited
Escientia Advanced Sciences Private Limited operates one associated brand: Escientia Lifesciences. These brands represent Escientia Advanced Sciences Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Technology-oriented manufacturing services for pharmaceutical and biotechnology firms are provided. | escientia.com |
Competitors & Alternatives of Escientia Advanced Sciences Private Limited
Brands and companies operating in the same space as Escientia Advanced Sciences Private Limited include LabCorp, Charles River Laboratories, Cytel and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
LabCorp
|
Provider of laboratory tests for physicians | Burlington, United States, United States | 1969 |
Charles River Laboratories
|
Provider of drug discovery and preclinical development services | Wilmington, United States, United States | 1947 |
Cytel
|
Data analysis and statistical solutions are provided for life sciences. | Cambridge, United States, United States | 1987 |
Precision Medicine Group
|
Provider of clinical research, development, and commercialization services for life sciences | Bethesda, United States, United States | 2012 |
Precision for Medicine
|
Company offering specialised R&D and clinical development services for the development of precision medicine based drugs and devices | Bethesda, United States, United States | 2013 |
Taimei Technology
|
A digital intelligence platform is focused on life sciences activities. | Pleasanton, United States, United States | 2013 |
Frontage Laboratories
|
Early drug development services are provided for pharma firms. | Exton, United States, United States | 2001 |
Scantox
|
Laboratory focused on providing pharmacology, toxicology, and histopathology services | Lille Skensved, Denmark, Denmark | 1977 |
Canopy Biosciences
|
Cell line engineering services are offered via CRISPR-Cas9 technology. | St. Louis, United States, United States | 2016 |
Veeda Clinical Research
|
Drug development services encompassing clinical trials, bioanalytical support, and real-world evidence in healthcare. | Ahmedabad, India, India | 2004 |
Business Activity of Escientia Advanced Sciences Private Limited
Escientia Advanced Sciences Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Board of Directors of Escientia Advanced Sciences Private Limited
Escientia Advanced Sciences Private Limited is currently managed by 6 directors, with 7 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Srinivasa Rao Korada | Cfo | 01 Mar 2021 | 5 Years 4 Months | Current |
|
Pendri Kiran Reddy
Also directs:
Escientia Biopharma Private Limited
|
Director | 27 Feb 2013 | 13 Years 4 Months | Current |
| Dandu Chakradhar | Director | 19 Aug 2020 | 5 Years 10 Months | Current |
|
Ajit Alexander George
Also directs:
Escientia Biopharma Private Limited
|
Director | 24 Jun 2023 | 3 Years 0 Months | Current |
| Yadagiri R Pendri | Director | 27 Feb 2013 | 13 Years 4 Months | Current |
| Vivek Vasant Save | Director | 24 Jun 2023 | 3 Years 0 Months | Current |
Financials of Escientia Advanced Sciences Private Limited FY 2024 filings available
Escientia Advanced Sciences Private Limited reported revenue of ₹423.15 Cr (up 114% YoY) for FY 2024. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Escientia Advanced Sciences Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Nov 2020 | Others | ₹100 Cr | Open |
| 29 Jun 2021 | Hdfc Bank Limited | ₹65 Cr | Satisfied |
| 02 Nov 2020 | Others | ₹20 Cr | Satisfied |
Total charge records: 3 View all charges
Employees and EPFO Compliance at Escientia Advanced Sciences Private Limited
View historical data on people associated with Escientia Advanced Sciences Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Escientia Advanced Sciences Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Escientia Advanced Sciences Private Limited
GSTIN & GST Filing Data of Escientia Advanced Sciences Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Escientia Advanced Sciences Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Escientia Advanced Sciences Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Escientia Advanced Sciences Private Limited
MSME Payment Delays by Escientia Advanced Sciences Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Escientia Advanced Sciences Private Limited
Subsidiaries & Group Companies of Escientia Advanced Sciences Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Escientia Advanced Sciences Private Limited with ownership details.
MCA Filings & Documents of Escientia Advanced Sciences Private Limited
MCA Filings & Documents of Escientia Advanced Sciences Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Escientia Advanced Sciences Private Limited
Frequently Asked Questions about Escientia Advanced Sciences Private Limited
Escientia Advanced Sciences Private Limited is an active private limited company in the pharma sector based in Shameerpet, Telangana, India. It was incorporated on 27 February 2013 (13+ years old) and is registered under CIN U24100TG2013PTC085962. The company has 295 employees.
Escientia Advanced Sciences Private Limited reported revenue of ₹423.15 Cr for FY 2024 (up 114.00% YoY).
The current directors of Escientia Advanced Sciences Private Limited are:
The primary industry of Escientia Advanced Sciences Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Escientia Advanced Sciences Private Limited can be reached at the registered office: Surveyno.54202 Plot No:Ds 14 Ikp Knowledge Park Kolthur Village, Shameerpet, Telangana, India – 500078, or through the website escientia.com.
The authorised capital is ₹22 Cr, and the paid-up capital is ₹21.49 Cr.